This week’s ThreatsDay Bulletin covers USB malware, fake crypto scams, CastleRAT, new cyber laws, and falling ransomware ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 Data suggest ...